Michael Daskalakis
Overview
Explore the profile of Michael Daskalakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagliuca S, Malard F, Mooyaart J, Daskalakis M, Gabellier L, Yakoub-Agha I, et al.
Blood Rev
. 2025 Feb;
:101272.
PMID: 39986989
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional...
2.
Jeker B, Thalmann L, Bacher U, Nilius H, Rhyner G, Sokler M, et al.
Bone Marrow Transplant
. 2024 Nov;
60(3):270-276.
PMID: 39548306
In fit patients with newly diagnosed myeloma, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is considered standard of care. For mobilization of CD34+ cells for ASCT, combined...
3.
Volery F, Banz Y, Heini A, Kronig M, Siegrist D, Daskalakis M, et al.
Case Rep Oncol
. 2024 Oct;
17(1):1087-1093.
PMID: 39474550
Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T...
4.
Arber C, Baerlocher G, Chalandon Y, Daskalakis M, Duchosal M, Fehr M, et al.
Swiss Med Wkly
. 2024 Oct;
154:3704.
PMID: 39463445
No abstract available.
5.
Novak U, Mooyaart J, Daskalakis M, Scheid C, Gabellier L, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1631-1634.
PMID: 39192081
No abstract available.
6.
Martinez Flores D, Akhoundova D, Seipel K, Legros M, Kronig M, Daskalakis M, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062189
Gemtuzumab ozogamicin (GO), a CD33-targeting antibody drug conjugate, previously showed longer relapse-free survival when combined with induction chemotherapy in patients with favorable-risk acute myeloid leukemia (AML). In this patient population,...
7.
Eggimann M, Akhoundova D, Nilius H, Hoffmann M, Hayoz M, Aebi Y, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791965
(1) Background: Treosulfan and melphalan (TreoMel)-based high-dose chemotherapy (HDCT) has shown promising safety and efficacy as a conditioning regimen for acute myeloid leukemia (AML) patients undergoing autologous stem cell transplantation...
8.
Mehl J, Akhoundova D, Bacher U, Jeker B, Rhyner Agocs G, Ruefer A, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791933
Daratumumab is being increasingly integrated into first-line multiple myeloma (MM) induction regimens, leading to improved response depth and longer progression-free survival. Autologous stem cell transplantation (ASCT) is commonly performed as...
9.
Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, et al.
Hemasphere
. 2024 Mar;
8(3):e54.
PMID: 38510993
CD19-directed chimeric antigen receptor (CAR)-T cell therapy has become a standard treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). While the benefits of CAR-T cell treatment are clear in...
10.
Zdanowicz J, Schneider S, Martignoni C, Lamari S, Fuchs A, Daskalakis M, et al.
J Clin Med
. 2023 Dec;
12(23).
PMID: 38068523
Postpartum hemorrhage (PPH) remains a major cause of maternal morbidity and mortality. While PPH treatment guidelines exist, data on their effect on reduction in red blood cell (RBC) transfusions and...